BeOne Medicines extends its collaboration with quantitative systems pharmacology firm InSysBio, aiming to optimize clinical trial dosing and mitigate cytokine release syndrome risks across its broad portfolio of 15 novel oncology assets.
Five years after its peak, Polkadot (DOT) trades at a staggering 97% discount from its all-time high. Once a top-tier crypto, it has now fallen outside the top 30. We examine whether its steep discount represents a hidden opportunity or a sign of a failed thesis in a market now dominated by Ethereum and Solana.
As financial institutions grapple with aging core systems like Gen, experts warn that deferring modernization in hopes of a future AI fix is compounding costs, risks, and missed opportunities in a rapidly evolving digital landscape.
India's government has reaffirmed its stringent cryptocurrency taxation framework in the latest budget, leaving the controversial 30% levy and 1% transaction tax unchanged, dashing industry hopes for reform and cementing a policy that has already driven billions in trading volume offshore.
Immunocore Holdings (IMCR) shares have experienced notable turbulence, declining over 7% in a week. Yet, a significant gap between its current price and analyst fair value estimates highlights a debate over the biotech's future, heavily reliant on its lead asset KIMMTRAK and pipeline execution.
Northwest Bancshares' Q4 results showcased the initial impact of its Penns Woods acquisition, boosting revenue and margins. While management struck a confident tone on integration, analyst questions during the earnings call revealed a sharper focus on the sustainability of growth, cost savings, and competitive pressures in a shifting rate environment.
Erasca (ERAS) gains significant analyst momentum as Mizuho initiates coverage with an 'Outperform' rating and a $16 price target, citing confidence in its 2026 proof-of-concept milestones for RAS-targeted cancer therapies.
Terns Pharmaceuticals has restructured a key licensing deal with China's Hansoh, gaining exclusive worldwide rights for its TERN-701 oncology drug outside Greater China. The strategic move, coupled with a recent analyst price target surge, signals the company's aggressive push into international markets.
Alphabet's self-driving subsidiary Waymo is reportedly seeking a new funding round that would value the company at approximately $110 billion, drawing fresh attention to the tech giant's ambitious bets beyond its core advertising business and the evolving landscape of autonomous vehicle investment.
While geopolitical tensions have rattled regional markets, a closer look reveals resilient smaller companies in the GCC and Turkey offering unique value propositions. We analyze three firms with market caps under $900 million in the education, packaging, and industrial sectors.
Exelixis shares have delivered impressive multi-year returns, but recent price weakness has investors questioning if the rally has run its course. A deep dive into valuation models suggests the stock may still be significantly undervalued, presenting a potential opportunity amidst market uncertainty.
D-Wave Quantum Inc. announces the relocation of its headquarters and core R&D from Palo Alto, California, to Boca Raton, Florida, citing the state's business climate and partnership opportunities, in a move emblematic of a wider coastal tech migration.
Sanofi's experimental oral drug venglustat demonstrated significant neurological benefits for patients with Type 3 Gaucher disease in a late-stage trial, but failed to meet its primary endpoint in a separate study for Fabry disease, casting uncertainty on its regulatory path.
Amidst a patchy economic recovery, European small-cap stocks are back in focus. A surge in insider buying activity points to potential undervaluation in select names across property, cybersecurity, and defense tech sectors.
Salesforce expands its enterprise footprint with a landmark $5.6 billion defense contract and a new role in an AI-driven wildfire response initiative, signaling a strategic push into mission-critical government and infrastructure sectors.
A software engineer who turned an early bet on Nvidia into a $20 million fortune and early retirement is now pointing to quantum computing as the frontier with similar explosive potential. His journey underscores the high-risk, high-reward nature of thematic investing.
While Boeing's Q4 revenue beat offers short-term relief, analysts point to its unprecedented order backlog as the true indicator of long-term recovery and growth potential in the commercial aviation sector.
BeOne Medicines (ONC) presents a complex picture for investors, with recent short-term volatility contrasting sharply with strong long-term returns. As the stock trades around $340, analysts debate whether its current price fully reflects the ambitious growth narrative in its oncology pipeline.
Faced with the realities of modern warfare in Ukraine, NATO is fast-tracking innovation, creating an unprecedented opportunity for agile tech founders to access a once-closed defense market.
The visual discovery platform Pinterest is cutting up to 15% of its global workforce as part of a strategic shift toward AI development, a move that has reignited concerns among its user base about the proliferation of AI-generated images flooding the platform.
